Skip to main content

Advertisement

SpringerLink
Log in

Clinical Trials of Neoadjuvant Chemotherapy for Ovarian Cancer: What Do We Gain After an EORTC Trial and After Two Additional Ongoing Trials Are Completed?

  • Invited Commentary
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The aim of neoadjuvant chemotherapy is to reduce the tumor volume or spread of the disease before the main treatment, and it could possibly make the main procedures easier or less invasive. Although the standard therapeutic strategy for advanced ovarian cancer is a maximum primary debulking surgery followed by chemotherapy, a European Organisation for Research and Treatment of Cancer (EORTC) prospective randomized trial demonstrated that neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to the standard procedure. This study raised a number of controversies, particularly regarding the quality of debulking surgery. To solve the questions, we need to wait for the results of two additional ongoing randomized trials. However, the results of those two trials must be carefully assessed, because the quality of debulking surgery would significantly affect survival, and may make the interpretation of the trial results more confusing and difficult.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21:750–5.

    Article  PubMed  Google Scholar 

  2. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.

    Article  PubMed  CAS  Google Scholar 

  3. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.

    Article  PubMed  CAS  Google Scholar 

  4. Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol. 2006;24:4531–3.

    Article  PubMed  Google Scholar 

  5. Thigpen T, duBois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011;21:756–62.

    Article  PubMed  Google Scholar 

  6. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.

    Article  PubMed  CAS  Google Scholar 

  7. Onda T, Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Rev Anticancer Ther. 2011;11:1053–67.

    Article  PubMed  Google Scholar 

  8. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103:1070–6.

    Article  PubMed  CAS  Google Scholar 

  9. Chi DS, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol. 2011;29:4073–5.

    Article  PubMed  CAS  Google Scholar 

  10. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124:10–4.

    Article  PubMed  Google Scholar 

  11. Vergote I, Trope CG, Amant F, Ehlen T, Reed NS, Casado A. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol. 2011;29:4076–8.

    Article  PubMed  CAS  Google Scholar 

  12. Onda T, Matsumoto K, Shibata T, et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol. 2008;38:74–7.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

Keiichi Fujiwara has been a consultant for Auro and Amgen and has received honoraria from Sanofi, Boehringer-Ingelheim, Taiho, Kyowa Kirin, Chugai, Zeria, Janssen, and GlaxoSmithKline.

Akira Kurosaki declares no conflict of interest.

Kosei Hasegawa declares no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, Saitama Medical School International Medical Center, 1397-1 Yamane, Hidaka-City, Saitama, 350-1298, Japan

    Keiichi Fujiwara, Akira Kurosaki & Kosei Hasegawa

Authors
  1. Keiichi Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Kurosaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kosei Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keiichi Fujiwara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujiwara, K., Kurosaki, A. & Hasegawa, K. Clinical Trials of Neoadjuvant Chemotherapy for Ovarian Cancer: What Do We Gain After an EORTC Trial and After Two Additional Ongoing Trials Are Completed?. Curr Oncol Rep 15, 197–200 (2013). https://doi.org/10.1007/s11912-013-0313-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-013-0313-9

Keywords

Search

Navigation